MADRID 2026 ESMO congress

4648P

Subgroup analyses from the ASCENT-04/KEYNOTE-D19 study of sacituzumab govitecan (SG) + pembrolizumab (Pembro) vs chemotherapy (Chemo) + Pembro in previously untreated advanced triple-negative breast cancer (TNBC)

E. de Azambuja[1], P. Schmid[2], K. Kalinsky[3], S. Loi[4], S-B. Kim[5], C. Yam[6], B.L. Rapoport[7], S-A. Im[8], B. Pistilli[9], W. Mchayleh[10], D. Cescon[11], J. Watanabe[12], M.A. Lara Bañuelas[13], R. Freitas[14], A. Iortholary[15], M. Afshari[16], A. Chen[17], D. Zhang[18], S.M. Tolaney[19]

[1] Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B) and Université Libre de Bruxelles (ULB), Brussels, Belgium, [2] Centre of Experimental Cancer Medicine, CenBarts Cancer Institute, Queen Mary University of London, London, United Kingdom, [3] Medicine Dept., Winship Cancer Institute of Emory University, Atlanta, United States of America, [4] Department of Oncology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia, [5] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, [6] Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America, [7] Clinical and Translational Research Unit, Medical Oncology Centre of Rosebank; Faculty of Health Sciences, University of Pretoria, Johannesburg, South Africa, [8] Internal Medicine Dept, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea, [9] Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France, [10] Department of Oncology, AdventHealth Cancer Institute, Orlando, United States of America, [11] Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, [12] Department of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan, [13] Departamento de Oncologia Medica, SCIENTIA Investigación Clínica, Guadalajara, Mexico, [14] CORA - Advanced Center for Diagnosis of Breast Cancer, Araujo Jorge Cancer Hospital, Goias Anticancer Association, Goiania, Brazil, [15] Department of Medical Oncology, Hopital Privé du Confluent, Nantes, France, [16] Clinical Development, Gilead Sciences, Inc., Foster City, United States of America, [17] Development Department, Gilead Sciences, Inc., Foster City, United States of America, [18] Department of Biostatistics Oncology, Gilead Sciences, Inc., Foster City, United States of America[19] Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, United States of America

Background

First-line (1L) SG + pembro showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs chemo + pembro in the ASCENT-04 study (HR 0.65) in participants (pts) with PD-L1+ locally advanced unresectable or metastatic TNBC. Efficacy results in subgroups of clinical interest from ASCENT-04 are reported.

Methods

Pts were randomized 1:1 to SG + pembro or chemo (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin [gem/carbo]) + pembro. Primary end point: PFS by blinded independent central review. An *ad hoc* analysis (data cutoff, Mar 3, 2025) was conducted in prespecified subgroups based on chemo selected prior to randomization in the overall population (taxane [tax], gem/carbo), disease status (*de novo* metastatic, recurrent within 6-12 mo, and > 12 mo), and presence of brain metastases (mets; yes/no). Visceral mets (yes/no) was also assessed (*post-hoc*).

Results

There were 443 pts (SG + pembro, 221; chemo + pembro, 222). Across subgroups, HR for PFS was < 1 (Table). Median (m)PFS was longer with SG + pembro vs chemo + pembro in pts preselected to receive tax or gem/carbo, pts with *de novo* metastatic disease, recurrent disease within 6-12 mo or > 12 mo, pts with and without visceral mets, and pts with and without brain mets, while acknowledging small sample size for pts with brain mets. Incidence of new lesions at time of progression was lower in the SG + pembro group (24%) vs chemo + pembro group (34%), with a smaller proportion of pts developing new visceral lesions in SG + pembro group (13% vs 18%, respectively).

Conclusions

This *ad hoc* analysis showed a consistent numerical PFS benefit with SG + pembro vs chemo + pembro across subgroups, with fewer pts developing new visceral lesions with SG + pembro. Findings were consistent with the overall population, further supporting SG + pembro as a 1L standard of care for pts with PD-L1+ advanced TNBC.Table: 4648P

	SG + Pembro		Chemo + Pembro	
	n	mPFS (95% CI), mo	HR (95% CI)	n	mPFS (95% CI), mo

	SG + Pembro		Chemo + Pembro		
	n	mPFS (95% CI), mo	HR (95% CI)	n	mPFS (95% CI), mo
Preselected chemo					
Tax	116	11.1 (8.6-16.7)	114	9.2 (7.2-12.9)	0.82 (0.58-1.17)
Gem/carbo	105	11.3 (9.2-21.2)	108	7.4 (6.9-9.0)	0.52 (0.36-0.75)
Disease					
De novo metastatic	75	8.1 (7.3-18.6)	75	7.7 (6.1-11.9)	0.89 (0.59-1.34)
Recurrent (6-12 mo)	40	9.9 (5.7-16.8)	40	7.2 (4.4-9.1)	0.62 (0.36-1.08)
Recurrent (> 12 mo)	106	16.6 (11.0-NR)	107	8.7 (7.3-10.8)	0.52 (0.35-0.76)
Visceral mets					
Yes	147	9.3 (7.7-11.7)	140	7.0 (5.6-7.5)	0.64 (0.47-0.85)
No	74	16.8 (12.9-NR)	82	9.9 (9.0-12.9)	0.64 (0.39-1.05)
Brain mets					
Yes	8	5.7 (0.5-NR)	6	3.7 (1.3-NR)	0.64 (0.19-2.14)
No	213	11.7 (9.3-16.8)	216	8.4 (7.4-9.3)	0.65 (0.50-0.84)

NR, not reached.

Clinical trial identification

NCT05382286.

Editorial acknowledgement

Medical writing and editorial assistance were provided by Jennifer Granit, PhD and Kanchan Bhati, M Pharm, of Parexel, and was funded by Gilead Sciences, Inc.

Legal entity responsible for the study

Gilead Sciences, Inc.

Funding

Gilead Sciences, Inc.

Disclosure

E. de Azambuja: Financial Interests, Personal, Advisory Board: Roche/GNE, Novartis, SeaGen, Lilly, MSD, Gilead, Bayer, Boehringer Ingelheim, Menarini-Stemline, AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca, Gilead Sciences, Boehringer Ingelheim; Financial Interests, Personal, Other, Chair of the Gilead Sciences Research Scholars Program in Solid Tumours: Gilead Sciences; Financial Interests, Personal, Other, Roche WO43571 IDMC: Roche/Genentech; Financial Interests, Institutional, Research Grant: Roche/GNE, AstraZeneca, GSK/Novartis; Financial Interests, Institutional, Local PI: MSD, ABCSG, Nektar, Gilead, Immunomedics, Synthon, Odonate Therapeutics; Financial Interests, , Steering Committee Member, ASCENT 04: Gilead; Financial Interests, , Steering Committee Member, Aphinity, Impassion30: Roche; Financial Interests, , Steering Committee Member, AURORA: Breast International Group; Financial Interests, , Steering Committee Member, Olympia: AstraZeneca; Financial Interests, Personal, Other, Travel Grant SABCS 2025: Gilead; Financial Interests, Institutional, Other, Scholarship grant for 2025-2026 for Luca Arecco: Gilead Sciences; Financial Interests, Institutional, Coordinating PI, Research grant for the TUCANIBE retrospective study: Pfizer; Financial Interests, Personal, Other, Travel grant to ESMO BREAST 2025: MSD; Financial Interests, Institutional, Research Grant, Scholarship for Luca Arecco: Gilead Sciences; Financial Interests, Institutional, Research Grant, Research Grant for my institution: Seagen; Financial Interests, Institutional, Local PI, HERMIA trial: absynth; Non-Financial Interests, , Advisory Role, Member of the cardio-oncology council: European Society of Cardiology (ESC), Belgian Society of Cardiology; Non-Financial Interests, , Advisory Role, Belgium governmental institution for cancer: KCE; Non-Financial Interests, , Other, Editorial board member: ESMO Open; Non-Financial Interests, , Advisory Role, As requested: Anticancer Fund; Non-Financial Interests, , Leadership Role, President 2023-2026: Belgian Society of Medical Oncology (BSMO); Non-Financial Interests, , Leadership Role, Executive Board Member: Breast International Group. P. Schmid: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Pfizer, Roche, Gilead, Daiichi Sankyo, MSD, Bicycle Therapeutics, Lilly, Summit Therapeutics, Olema Oncology; Financial Interests, Personal, Invited Speaker: Menarini-Stemline, Gilead, AstraZeneca, Daiichi Sankyo, MSD, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Genentech, Roche. K. Kalinsky: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Eli-Lilly, Pfizer, Novartis, AstraZeneca, Merck, Seattle Genetics, Puma, Genentech, Gilead, Menarini, myovant, Mersana Therapeutics, proteinqure, biotheranostics, Regor, Relay Therapeutics; Financial Interests, Personal, Other, Consultant: Rayzbio, Jazz Pharmaceuticals, Myovant, Takeda, Menarini, Prelude; Financial Interests, Institutional, Other, Consultant: Bicycle Therapeutics; Financial Interests, Personal, Stocks/Shares, Employment

+ Stock = spouse: Grail; Financial Interests, Personal, Stocks/Shares, Spouse: ADC Therapeutics; Financial Interests, Personal and Institutional, Local PI, Consultant: Novartis, Eli-Lilly, Astra Zeneca, daicchi sankyo; Financial Interests, Personal and Institutional, Local PI, consultant: Genentech; Financial Interests, Institutional, Local PI, consultant: Pfizer; Financial Interests, Institutional, Local PI: Seattle Genetics, Ascentantage; Financial Interests, Personal, Other, consultant: RayzeBio; Other, , Other, Support for attending meetings and/or travel: Eli-Lilly, AstraZeneca, Pfizer; Other, , Other, Steering Committee: Immunomedics, AstraZeneca, Ambryx, Genentech. S. Loi: Financial Interests, Institutional, Advisory Board, Consultant: AstraZeneca / Daiichi Sankyo, Novartis, Roche Genentech; Financial Interests, Institutional, Advisory Board, COnsultant: BMS; Financial Interests, Institutional, Advisory Board, consultant: Eli Lilly, Gilead Sciences, MSD; Financial Interests, Personal, Advisory Board: Novartis, AstraZeneca / Daiichi Sankyo, BMS, Amaroq Therapeutics, Mersana Therapeutics, Domain Therapeutics, Menari Asia-Pacific, Gilead Sciences, MSD, Roche Genentech, Bicycle Therapeutics, Pfizer, Eli Lilly, BioNTech, Exact Science, SAGA Diagnostics, Adanate; Financial Interests, Institutional, Funding: Novartis, BMS, MSD, Eli Lilly, AstraZeneca / Daiichi Sankyo, Roche - Genentech, Gilead Sciences, Pfizer; Non-Financial Interests, , Advisory Role, Consultant (Non remunerated): Seattle Genetics, Novartis, Bristol Myers Squibb, Merck, AstraZeneca, Roche Genentech; Non-Financial Interests, , Advisory Role, consultant (not compensated): Eli Lilly, Gilead Therapeutics. S. Kim: Financial Interests, Personal, Advisory Board: AstraZeneca, Lilly, DaeHwa Pharma, Daiichi-Sankyo, Beigene, BNT, TiumBio, Novartis; Financial Interests, Personal, Other, Medical travel: Lilly. C. Yam: Financial Interests, Institutional, Advisory Board, reimbursement for travel: Gilead; Financial Interests, Institutional, Invited Speaker: MDHealth Brazil, Binaytara Foundation, PRIME Education; Financial Interests, Institutional, Local PI: Gilead, Amgen, Merck, Pfizer, Astellas, Genentech, Novartis, BostonGene; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Steering Committee Member: Gilead; Non-Financial Interests, , Advisory Role, Scientific Advisory Board: CytoDyn; Non-Financial Interests, , Advisory Role, Advisory Board: Y-mAbs Therapeutics. B.L. Rapoport: Financial Interests, Personal, Advisory Board: Roche South Africa, J&J South Africa, Pfizer South Africa, AstraZeneca South Africa; Financial Interests, Personal, Invited Speaker, Presentation regarding the use of CDK 4/6 in breast cancer: Aspen South Africa. S. Im: Financial Interests, Personal, Advisory Board, no payment: AstraZeneca, Novartis, Eisai, Roche, Pfizer, Lilly, MSD, Daiichi-Sankyo, SK Biopharmaceuticals Co., Ltd., Gilead Sciences; Financial Interests, Institutional, Research Grant: AstraZeneca, Pfizer, Roche, Eisai; Financial Interests, Institutional, Local PI, Clinical Trial Budget: AstraZeneca, Novartis, Roche, Pfizer, Daiichi-Sankyo, MSD, Lilly; Financial Interests, Institutional, Coordinating PI, Clinical Trial Budget: Eisai; Financial Interests, Institutional, Research Grant, Clinical Trial Budget: Boryung Pharm. B. Pistilli: Financial Interests, Institutional, Advisory Board: ASTRA ZENECA, SEAGEN, LILLY, DAIICHI-SANKYO, MSD; Financial Interests, Institutional, Invited Speaker: GILEAD, NOVARTIS; Financial Interests, Personal, Advisory Board: PIERRE FABRE, DAIICHI-SANKYO; Financial Interests, Personal, Other, travel support: ASTRA ZENECA, PIERRE FABRE, MSD, DAIICHI-SANKYO, Gilead; Financial Interests, Personal, Other, Travel support: PFIZER; Financial Interests, Institutional, Advisory Board, Advisory Board and member of Steering Committee: OLEMA; Financial Interests, Institutional, Steering Committee Member: ASTRA ZENECA, NOVARTIS; Financial Interests, Institutional, Research Grant: ASTRA ZENECA; Financial Interests, Institutional, Local PI: ASTRA ZENECA, GILEAD, SEAGEN, MSD, NOVARTIS; Financial Interests, Institutional, Funding: DAIICHI-SANKYO; Non-Financial Interests, , Project Lead: UNICANCER. W. Mchayleh: Financial Interests, Personal, Advisory Board: Lilly, AstraZeneca, Gilead, Menarini-Stemline; Financial Interests, Personal, Invited Speaker: Lilly, AstraZeneca, Gilead, Menarini-Stemline, Merck, Natera, Daiichi Sankyo, Daiichi Sankyo; Financial Interests, Personal, Stocks/Shares: tempus, Natera, Relay Therapeutics, BMS. D. Cescon: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Exact Science, GenomeRx, Gilead, Lilly, Merck, Novartis, Pfizer, Roche, SAGA, Knight Therapeutics; Financial Interests, Institutional, Funding, Research funding (non-clinical), Local PI, Steering Committee Member: AstraZeneca; Financial Interests, Institutional, Research Grant: GenomeRx, ProteinQure, SAGA, Pear Bio; Financial Interests, Institutional, Local PI: Gilead, Pfizer, RayzeBio; Financial Interests, Institutional, Funding, Research Funding, Local PI and Steering Committee Member: GlaxoSmithKline; Financial Interests, Institutional, Funding, Research: Grail; Financial Interests, Institutional, Other, Collaborative Research Agreement: Guardant Health; Financial Interests, Institutional, Other, Research funding and in-kind support: Inivata/NeoGenomics; Financial Interests, Institutional, Other, In kind support of research: Knight Therapeutics; Financial Interests, Institutional, Funding, Local PI and Steering Committee Member: Merck; Non-Financial Interests, , Advisory Role: Canadian Breast Cancer Network. J. Watanabe: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Gilead Sciences, MSD, Pfizer, Kyowa-Kirin; Financial Interests, Institutional, Local PI: AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly Japan, Gilead Sciences, MSD, Pfizer, Jazz Pharmaceuticals; Non-Financial Interests, , Leadership Role: Japanese Breast Cancer Society, Japan Organization of Hereditary Breast and Ovarian Cancer; Non-Financial Interests, , Member: American Society of Clinical Oncology, European Society For Medical Oncology. M.A. Lara Bañuelas: Financial Interests, Personal, Advisory Board: MSD, Johnson and Johnson; Financial Interests, Personal, Invited Speaker: Bayer, Gilead; Non-Financial Interests, , Principal Investigator: Gilead. R. Freitas Jr: Financial Interests, Institutional, Invited Speaker: Novartis, MSD, Gilead, AstraZeneca, Roche, Daiichi Sankyo; Financial Interests, Institutional, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant, As a Principal investigator of ITABERAI randomized trial: Itaberai. M. Afshari: Financial Interests, Personal, Full or part-time Employment: Gilead Sciences; Financial Interests, Personal, Stocks/Shares: Gilead Sciences. A. Chen: Financial Interests, Personal, Full or part-time Employment: Gilead Sciences, Inc; Financial Interests, Personal, Stocks or ownership: Gilead Sciences, Inc. D. Zhang: Financial Interests, Personal, Full or part-time Employment: Gilead Sciences; Financial Interests, Personal, Stocks/Shares: Gilead Sciences. S.M. Tolaney: Financial Interests, Personal, Other, Consulting: Aadi BioPharma, Hengrui, Avenzo Therapeutics, Atkis Oncology, Celcuity, Samsung Bioepis, Tempus; Financial Interests, Personal, Advisory Board, Ad board participation: Artios, Bicycle Therapeutics; Financial Interests, Personal, Advisory Board, Ad Board Participant/Consultant: AstraZeneca, Eli Lilly; Financial Interests, Personal, Advisory Board, Advisory Board participation: Bayer, Sumitovant Biopharmaceuticals, Natera; Financial Interests, Personal, Other, Consultant: Blueprint Medicines, Boundless Bio, Denali Therapeutics; Financial Interests, Personal, Advisory Board, Ad board participant: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Board, Ad board participant/consultant: Daichii Sankyo, Eisai, Genentech/Roche, Gilead, Novartis, SeaGen; Financial Interests, Personal, Advisory Board, Advisory Board participation/consulting: Menarini/Stemline, BeOne Medicines; Financial Interests, Personal, Advisory Board, Ad

Board participant/consultant: Merck; Financial Interests, Personal, Advisory Board, Ad board participant/Consultant: Pfizer; Financial Interests, Personal, Advisory Board, Advisory board participation: Reveal Genomics, Launch Therapeutics; Financial Interests, Personal, Advisory Board, Advisory board/consulting: Jazz Pharma; Financial Interests, Personal, Advisory Board: Tango Therapeutics, Systimmune, eFFECTOR, Cullinan Oncology, Arvinas, Boehringer Ingelheim; Financial Interests, Personal, Advisory Board, Ad Board participation: Summit Therapeutics; Financial Interests, Personal, Advisory Board, ad board participation: BioNTech, Circle Pharma; Financial Interests, Personal, Advisory Board, Ad board/consulting participation: Zuellig Pharma; Financial Interests, Personal, Advisory Board, ad board/consulting participation: Johnson&Johnson/Ambrx; Financial Interests, Personal, Advisory Board, Advisory Board participation and consulting activities: Mersana Therapeutics; Financial Interests, Personal, Advisory Board, Steering Committee: Olema Pharmaceuticals; Financial Interests, Institutional, Coordinating PI, And steering committing: AstraZeneca; Financial Interests, Institutional, Local PI, And steering committee: Eli Lilly, Jazz Pharmaceuticals; Financial Interests, Institutional, Local PI: Pfizer, SeaGen, Novartis, Nanostring, Bristol Myers Squibb, Daiichi Sankyo; Financial Interests, Institutional, Funding: Exelixis, OncoPep; Financial Interests, Institutional, Coordinating PI, and steering committee: Gilead; Financial Interests, Institutional, Local PI, and steering committee: Merck, Genentech/Roche, Stemline/Menarini; Other, , Other, Travel Support: Eli Lilly, Gilead Sciences, Jazz Pharmaceuticals, Arvinas, Roche – Genentech, AstraZeneca. All other authors have declared no conflicts of interest.

© European Society for Medical Oncology